Dear EURETINA Members, A very warm welcome to the September 9th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »September 9th, 2024 “EURETINA-Brief” Issue No. 299
Researchers at Moorfields Eye Hospital, the UCL Institute of Ophthalmology, University College London and the Shiley Eye Institute, University of California, San Diego, has reported… Read More »Variants on the TMEM216 gene suggests an under-reporting from certain ancestry cohorts on non-syndromic retinitis pigmentosa (RP).
Researchers at the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy and the Department of Ophthalmology, University of Oslo, Norway, have published a… Read More »A systematic review of retinitis pigmentosa and its therapeutic approaches report different treatments and disorders.
Merck (NYSE: MRK) has recently announced the completion of the acquisition of Eyebiotech Limited (EyeBio), now becoming a wholly-owned subsidiary of Merck. EyeBio was founded… Read More »Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).
Dear EURETINA Members, A very warm welcome to the August 23rd, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 23rd, 2024 “EURETINA-Brief”© Issue No. 298
Researchers at the Department of Ophthalmology, Boston Children’s Hospital, and the Harvard Medical School, have reported that the interface of photoreceptors and RPE in Stargardt… Read More »Analysis of data from AO-SLO images on Stargardt disease patients show clear profiles of hyper-reflective bands, potentially targeted for pharmaceutical treatment.
An international consortium of researchers on a multi-centre study on congenital stationary night blindness (CSNB), led by Oregon Health and Science University Casey Eye Institute,… Read More »An international multi-centre study on congenital stationary night blindness (CSNB) report several genetic variants on myopia.
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), based in Emeryville, California, have announced interim 24-week data from their “PRISM” (WET AMD) and “SPECTRA” (DME) phase I/II… Read More »Positive results from 4DMT announce an improvement on BCVA for a dual-transgene treatment for wet AMD and DME.
Dear EURETINA Members, A very warm welcome to the August 8th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 8th, 2024 “EURETINA-Brief”© Issue No. 297
In a recent study published in the prestigious journal Nature Communications (2024 Jul 21;15[1]:6150), researchers have reported that an upstream regulator, “AKT2” (a member of… Read More »Researchers identify that lysosomal biogenesis and mitochondrial signalling may suggest new therapeutic targets for dry-AMD.
